Asieris Pharma Completes Patient Enrollment in Hexvix's Phase III Bridging trial for the Diagnosis of Bladder Cancer

Asieris Pharmaceuticals, a global biopharmaceutical company specialising in the discovery, development, and commercialization of innovative drugs for the treatment of genitourinary tumours and other related diseases, announced the completion of patient enrollment for its phase III bridging clinical trial of Hexvix, a drug used to diagnose bladder cancer. The study is a prospective, self-controlled, multicenter phase? trial comparing Hexvix and blue light cystoscopy (BLC) to white light cystoscopy (WLC) in patients with non-muscle invasive bladder cancer (NMIBC), including tumours with stages carcinoma in situ (CIS), Ta, and T1. Peking Union Medical College Hospital and the Chinese Academy of Medical Sciences are leading this research.

Professor Li Hanzhong, head of the Department of Surgery at Peking Union Medical College Hospital, is the Principal Investigator for this study, leading a team of top bladder cancer experts in China. Asieris signed a licence agreement with Photocure ASA, a bladder cancer specialty company based in Oslo, Norway, in January 2021 to obtain the exclusive registration and commercialization rights to Hexvix in mainland China and Taiwan. “Completing patient enrollment for the phase III bridging clinical trial of Hexvix marks a significant milestone for Asieris Pharmaceuticals.” said Dr. Linda Wu, chief development officer of Asieris,” We are thrilled to have reached this stage in the development of a drug that has the potential to revolutionize the diagnosis of bladder cancer. Our goal is to provide healthcare professionals with a more effective and reliable way for patient with bladder cancer.”